TW202444700A - 作為sarm1抑制劑之經取代1h-吡唑-4-甲醯胺化物 - Google Patents

作為sarm1抑制劑之經取代1h-吡唑-4-甲醯胺化物 Download PDF

Info

Publication number
TW202444700A
TW202444700A TW113102816A TW113102816A TW202444700A TW 202444700 A TW202444700 A TW 202444700A TW 113102816 A TW113102816 A TW 113102816A TW 113102816 A TW113102816 A TW 113102816A TW 202444700 A TW202444700 A TW 202444700A
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
pyrazole
Prior art date
Application number
TW113102816A
Other languages
English (en)
Chinese (zh)
Inventor
陶德 波薩納克
安德魯 賽門 布雷利
拉杰什 德芙拉吉
羅伯特 歐文 修斯
雪莉 安妮 帕勒特
Original Assignee
美商達薩瑪治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商達薩瑪治療公司 filed Critical 美商達薩瑪治療公司
Publication of TW202444700A publication Critical patent/TW202444700A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW113102816A 2023-01-24 2024-01-24 作為sarm1抑制劑之經取代1h-吡唑-4-甲醯胺化物 TW202444700A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363481202P 2023-01-24 2023-01-24
US63/481,202 2023-01-24

Publications (1)

Publication Number Publication Date
TW202444700A true TW202444700A (zh) 2024-11-16

Family

ID=89983825

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113102816A TW202444700A (zh) 2023-01-24 2024-01-24 作為sarm1抑制劑之經取代1h-吡唑-4-甲醯胺化物

Country Status (7)

Country Link
US (1) US20260226056A1 (enExample)
EP (1) EP4655295A1 (enExample)
JP (1) JP2026503618A (enExample)
CN (1) CN120826394A (enExample)
AR (1) AR131685A1 (enExample)
TW (1) TW202444700A (enExample)
WO (1) WO2024158607A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025243724A1 (ja) * 2024-05-20 2025-11-27 国立研究開発法人国立精神・神経医療研究センター 神経保護剤
WO2026104424A1 (en) * 2024-11-14 2026-05-21 F. Hoffmann-La Roche Ag Sarm1 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3102645A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
AU2021206651B2 (en) 2020-01-07 2024-02-22 Disarm Therapeutics, Inc. Inhibitors of SARM1

Also Published As

Publication number Publication date
JP2026503618A (ja) 2026-01-29
US20260226056A1 (en) 2026-08-06
EP4655295A1 (en) 2025-12-03
WO2024158607A1 (en) 2024-08-02
AR131685A1 (es) 2025-04-23
CN120826394A (zh) 2025-10-21

Similar Documents

Publication Publication Date Title
AU2019283921B2 (en) Indole carboxamide compounds useful as kinase inhibitors
JP6918088B2 (ja) Ｇｐｒ１３９のモジュレーターとしての４−オキソ−３，４−ジヒドロ−１，２，３−ベンゾトリアジン
AU2017378324B2 (en) Bycyclic heteroaryl derivatives as CFTR potentiators
CN102482219B (zh) 吡喃酮和吡啶酮衍生物的制备方法
CA2409743C (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
KR101850661B1 (ko) 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용
JP5498703B2 (ja) プロテインキナーゼのインヒビターとして有用なチオフェン−カルボキサミド
JP2022517723A (ja) Ｃｄｋ阻害剤としての大環状化合物、その製造方法及びその医薬品における応用
AU2009262241A1 (en) 1, 2 disubstituted heterocyclic compounds
WO2003068773A1 (en) Pyrazolopyridine derivatives
CN101646671A (zh) 用作蛋白激酶抑制剂的化合物
TWI448465B (zh) 乙炔基衍生物
AU2009345802B2 (en) Phenoxymethyl heterocyclic compounds
CN101965347B (zh) 作为激酶抑制剂的吡唑并吡啶
CN101448832A (zh) 醛固酮合酶和/或11β-羟化酶抑制剂
WO2015077193A1 (en) Inhibitors of lysine methyl transferase
TW201040191A (en) Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
CA2770320A1 (en) Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
CN113166105B (zh) 作为cdk-hdac双通路抑制剂的杂环化合物
JP2019509272A (ja) 脊髄性筋萎縮症の治療のための併用療法
JP2009524682A (ja) アナバシン誘導体、医薬組成物およびその使用方法
WO2020143763A1 (zh) 卤代烯丙基胺类化合物及其应用
JP2026503618A (ja) Ｓａｒｍ１阻害剤としての置換された１ｈ－ピラゾール－４－カルボキサミド
JP2010510216A (ja) プロテインキナーゼのインヒビターとして有用な化合物
CN101484457B (zh) 作为用于治疗增殖病症的蛋白激酶PLK1抑制剂的4,5-二氢-[1,2,4]三唑并[4,3-f]蝶啶